Luxiq Foam
Perrigo Announces Commercial Launch Of Betamethasone Foam
Perrigo Co. Tuesday announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced.
Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam
Perrigo Co. (Nasdaq: PRGO) Tuesday announced that its partner, Cobrek Pharmaceuticals Inc., received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for betamethasone valerate foam 0.12 percent, the generic equivalent of Luxiq Foam.


















